Boon, DenaliRedd, Andrew D.Laeyendecker, OliverEngle, Ronald E.Nguyen, HanhOcama, PonsianoBoaz, IgaNdyanabo, AnthonyKiggundu, ValerianReynolds, Steven J.Gray, Ronald H.Wawer, Maria J.Purcell, Robert H.Kirk, Gregory D.Quinn, Thomas C.Stabinski, Lara2022-04-302022-04-302018Boon, D., Redd, A. D., Laeyendecker, O., Engle, R. E., Nguyen, H., Ocama, P., ... & Rakai Health Sciences Program. (2018). Hepatitis E virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda. The Journal of Infectious Diseases, 217(5), 785-789. DOI: 10.1093/infdis/jix61010.1093/infdis/jix610https://nru.uncst.go.ug/handle/123456789/3074A cross-sectional study was conducted of 500 human immunodeficiency virus (HIV)-infected adults frequency matched on age, sex, and community to 500 HIV-uninfected individuals in the Rakai District, Uganda to evaluate seroprevalence of anti-hepatitis E virus (HEV) IgG antibodies. HEV seroprevalence was 47%, and 1 HIV-infected individual was actively infected with a genotype 3 virus. Using modified Poisson regression, male sex (prevalence ratios [PR] = 1.247; 95% confidence interval [CI], 1.071–1.450) and chronic hepatitis B virus infection (PR = 1.377; 95% CI, 1.090–1.738) were associated with HEV seroprevalence. HIV infection status (PR = 0.973; 95% CI, 0.852–1.111) was not associated with HEV seroprevalence. These data suggest there is a large burden of prior exposure to HEV in rural Uganda.enhepatitis E virusViral hepatitisHEV seroprevalenceUgandaRakaiArticle